Earning his B.S. in Chemistry from the University of California, Berkeley, Scott Rocklage further pursued a Ph.D. in Chemistry from the Massachusetts Institute of Technology. During his pursuit of a Ph.D., Rocklage conducted research in Richard R. Schrock’s laboratory. A vast knowledge in chemistry, Rocklage has spent over 20 years of his career in healthcare management. Scott Rocklage is currently the managing partner at 5AM Ventures.
Under his leadership at 5AM Ventures, Rocklage successfully approved three U.S. New Drug Applications that include Omniscan, Cubicin and Teslascan. Since the approval of three new drug treatments by the FDA, six more drug candidates have entered into clinical trials.
5AM Ventures is a venture capital firm where Rocklage works closely with scientists, business-executives and physicians to form future life-saving medicines. Focused on meeting the medical needs of tomorrow, Rocklage is now working on identifying specific genotypes or mutations to better treat cancer.
Over the years, Rocklage has filled a variety of positions including Chairman and CEO of Cubist Pharmaceuticals and President and CEO of Nycomed Salutar, Inc. Rocklage is also the current Board Chairman of Rennovia, Kinestral and Cidara. He further served on the Boards of Pulmatrix and EPIRUS Biopharmaceuticals, Inc as well.
He previously was the Executive Chairman of Ilypsa, Semprus and Miikana. Currently Rocklage works out of the Boston, Massachusetts office where his typical day consists of Board meetings and studying new aspects of life sciences. To date, Scott Rocklage has the prestigious honor of being a co-inventor or inventor of more than 30 U.S. patents and written over 100 peer-reviewed publications.